Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders.

Friedman D, French JA, Maccarrone M.

Lancet Neurol. 2019 May;18(5):504-512. doi: 10.1016/S1474-4422(19)30032-8. Epub 2019 Mar 22. Review. Erratum in: Lancet Neurol. 2019 Apr 12;:.

PMID:
30910443
2.

Cannabinoids in treatment-resistant epilepsy: A review.

O'Connell BK, Gloss D, Devinsky O.

Epilepsy Behav. 2017 May;70(Pt B):341-348. doi: 10.1016/j.yebeh.2016.11.012. Epub 2017 Feb 8. Review.

PMID:
28188044
3.

Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D.

Epilepsia. 2014 Jun;55(6):791-802. doi: 10.1111/epi.12631. Epub 2014 May 22. Review.

4.

Medical Use of Cannabinoids.

Fraguas-Sánchez AI, Torres-Suárez AI.

Drugs. 2018 Nov;78(16):1665-1703. doi: 10.1007/s40265-018-0996-1. Review.

PMID:
30374797
5.

Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.

Hussain SA, Zhou R, Jacobson C, Weng J, Cheng E, Lay J, Hung P, Lerner JT, Sankar R.

Epilepsy Behav. 2015 Jun;47:138-41. doi: 10.1016/j.yebeh.2015.04.009. Epub 2015 Apr 29.

PMID:
25935511
6.

Investigational cannabinoids in seizure disorders, what have we learned thus far?

Ružić Zečević D, Folić M, Tantoush Z, Radovanović M, Babić G, Janković SM.

Expert Opin Investig Drugs. 2018 Jun;27(6):535-541. doi: 10.1080/13543784.2018.1482275. Epub 2018 Jun 6. Review.

PMID:
29842819
7.

Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.

Perry MS.

Epilepsy Curr. 2019 Mar-Apr;19(2):93-95. doi: 10.1177/1535759719835671.

PMID:
30955420
8.

Cannabinoids for epilepsy: What do we know and where do we go?

Brodie MJ, Ben-Menachem E.

Epilepsia. 2018 Feb;59(2):291-296. doi: 10.1111/epi.13973. Epub 2017 Dec 6. Review.

9.

Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder.

Dale T, Downs J, Olson H, Bergin AM, Smith S, Leonard H.

Epilepsy Res. 2019 Mar;151:31-39. doi: 10.1016/j.eplepsyres.2019.02.001. Epub 2019 Feb 5. Review.

PMID:
30771550
10.

Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.

Lattanzi S, Trinka E, Russo E, Striano P, Citraro R, Silvestrini M, Brigo F.

Drugs Today (Barc). 2019 Mar;55(3):177-196. doi: 10.1358/dot.2019.55.3.2909248.

PMID:
30938373
11.

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.

Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J, Nangia S, Singhal NS, Wilson CA, Patel A, Cilio MR.

Lancet Neurol. 2016 Mar;15(3):270-8. doi: 10.1016/S1474-4422(15)00379-8. Epub 2015 Dec 24. Erratum in: Lancet Neurol. 2016 Apr;15(4):352.

PMID:
26724101
12.

Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.

Rosenberg EC, Patra PH, Whalley BJ.

Epilepsy Behav. 2017 May;70(Pt B):319-327. doi: 10.1016/j.yebeh.2016.11.006. Epub 2017 Feb 9. Review.

13.

Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence.

Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, Herkes GK, Farrell M, Degenhardt L.

J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):741-753. doi: 10.1136/jnnp-2017-317168. Epub 2018 Mar 6. Review.

PMID:
29511052
14.

Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.

Porter BE, Jacobson C.

Epilepsy Behav. 2013 Dec;29(3):574-7. doi: 10.1016/j.yebeh.2013.08.037.

15.

Efficacy of cannabinoids in paediatric epilepsy.

Ali S, Scheffer IE, Sadleir LG.

Dev Med Child Neurol. 2019 Jan;61(1):13-18. doi: 10.1111/dmcn.14087. Epub 2018 Nov 6. Review.

PMID:
30402932
16.

Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?

Perucca E.

J Epilepsy Res. 2017 Dec 31;7(2):61-76. doi: 10.14581/jer.17012. eCollection 2017 Dec. Review.

17.

Cannabis for paediatric epilepsy: challenges and conundrums.

Chen KA, Farrar MA, Cardamone M, Lawson JA.

Med J Aust. 2018 Feb 19;208(3):132-136.

PMID:
29438649
18.

Endocannabinoid System: A Multi-Facet Therapeutic Target.

Kaur R, Ambwani SR, Singh S.

Curr Clin Pharmacol. 2016;11(2):110-7. Review.

PMID:
27086601
19.

Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.

Podda G, Constantinescu CS.

Expert Opin Biol Ther. 2012 Nov;12(11):1517-31. doi: 10.1517/14712598.2012.721765. Epub 2012 Sep 7. Review.

PMID:
22954177
20.

The potential role of cannabinoids in epilepsy treatment.

De Caro C, Leo A, Citraro R, De Sarro C, Russo R, Calignano A, Russo E.

Expert Rev Neurother. 2017 Nov;17(11):1069-1079. doi: 10.1080/14737175.2017.1373019. Epub 2017 Sep 4. Review.

PMID:
28845714

Supplemental Content

Support Center